Dhanalakshmi et al. (2002) demonstrated that silibinin inhibits both constitutive and TNF-α-induced NF-κB activation in cancer cells, blocking IκB-α phosphorylation and subsequent nuclear translocation of the p65 subunit [27]. The gene discussed is NFKB1; the disease is cancer.